OTX015

Target: This ligand targets BET-family bromodomains, including BRD2, BRD3, BRD4, and BRDT in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for BET-family bromodomains, including BRD2, BRD3, BRD4, and BRDT. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings BET-family bromodomains into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Mediated Degradation Studies: OTX015 can be used as a ligand component in PROTAC constructs to engage its intended binding partner and recruit an E3 ligase, enabling targeted ubiquitination and proteasomal degradation. This approach supports mechanistic studies comparing degradation potency versus occupancy, and mapping how ligand engagement drives downstream loss of the target protein.

• E3 Ligase Recruitment Optimization: Incorporating OTX015 into PROTAC designs allows systematic variation of linker length, attachment sites, and E3 ligase ligands to tune ternary complex formation. Researchers can evaluate how these parameters affect degradation kinetics, selectivity, and resistance to ubiquitin-proteasome pathway bottlenecks, using time-course degradation assays and quantitative proteomics.

• Target Specificity and Selectome Profiling: PROTACs built with OTX015 can be deployed to assess on-target versus off-target degradation effects across cell models. By measuring protein-level outcomes rather than only binding, investigators can perform selectome analyses to identify co-degraded proteins, validate pathway dependencies, and refine ligand architecture for improved specificity.

• Mechanistic Biomarker Discovery: Using OTX015-based PROTACs in controlled perturbation experiments enables identification of biomarkers linked to target degradation, such as transcriptional responses, pathway rewiring, and cell-state transitions. These studies help connect degradation magnitude with functional phenotypes, supporting rational selection of readouts for future PROTAC optimization and mechanistic validation.

OTX015 is a BET bromodomain target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of OTX015 is characterized by amide/urea/sulfonamide hydrogen-bonding motifs; phenol or alcohol functionality; halogenated aryl/heteroaryl ring system; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The hydroxy or phenolic motif can be considered for ether, carbonate, carbamate, or ester linker attachment after SAR verification. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.